focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Kaeren - my thoughts exactly. If you were allowed to buy 20 brands and now only allowed 10, surely, the revenue from the axed 10 gets distributed across the remaining 10. Testing aint going away. A mini profit warning is strange.
Also, what forward planning have Ncyt done in anticipation that their tests won't get approved on time (or won't get approved at all)? Could have put a paragraph about that into the RNS surely.
By the way, any reasons why they can't just sell Promate to those who were buying other tests?
The PR team should be tied to a Reliant Robin and dragged down the M25 for this RNS. Get somebody with half a brain to word them.
A spanking would be good for DA for signing off this sh.t.
Seriously though, could they possibly have worded that RNS any worse?
Did DA get selected for the job because he had even less charisma than GM?
F.cks sake, how about "NCYT are pleased to announce that following the implementation of the new UK regulations, ProMate is one of the X remaining tests that are still allowed to be sold in the UK"?!
"if I had a pound for every time I read on here:
"Eventually the tide will turn though and this will come good"."
If you hold on to your shares, you'll probably have more that a pound per each time you've read that.
Blue moon of Nova keep on shining
On the SP that's gone and proved untrue
Blue moon of Nova keep on shining
On the SP that's red but once was blue.
It was on a moonlight night
The stars were shining bright
And they whispered from on high
GM has said good-bye
Blue moon of Nova keep on shining
On profits that are gone and said good-bye.
The big question is - how long is covid testing going to last. I think it's here to stay for a very long time - you get the symptoms, you get a test to see if it's covid/flu/rsv. Even if covid becomes just another cold by this time next year. Current testing regime in the UK is *******s. The rest of the world seems to be similar.
The covid cash cow is not dead yet.
The rest of the diagnostics are probably worth more as a takeover target than as a direct cash earner for the company.
"Uninvestable" is not a term I'd apply here - on the contrary, the company is generating cash, is very cash-rich and has excellent R&D to cash in on future opportunities. It's frustrating as f.ck that sp keeps falling, but the fundamentals are as good as they get.
Downside is very limited, upside is infinity and beyond. This is better than almost anything on AIM. Sure, you get companies with better upside prospects but that's almost always offset by crippling downside and the need to constantly dilute to inject cash.
You want to put money into SNG, be my guest, just make sure you know EXACTLY what you're punting on. DYOR.
For some reason they seem to have strong II support, unlike ncyt. But the downside there is huge. Last time IIs changed their mind about marsden juice, sp went from 220p to 80p. Great if you can buy at 80p, not great if you bought into the hype at 220. Marsden's a cunning wee ****er - he even managed to spike IIs last year.
Ncyt is pretty much at the bottom right now and the downside, imho, is negligible - we're almost trading at cash position.
Compare a pure covid-play-that's-never-made-a-penny SNG mcap with cash generating NCYT and make your own decisions.
Getting a bit sick of folks cross ramping on this board.